Pfizer Assists Ada Health to Help Potential COVID-19 Patients Receive Timely Treatment Via Online Service

An online condition-based care service designed to help people understand if they meet the criteria for progression to severe COVID-19 was launched under the partnership of Pfizer and Ada Health.

COVID-19 Care Journey, the digital platform operated by Ada and developed with Pfizer — which manufactures the Paxlovid antiviral — not only informs users if they meet severe COVID but can also connect them with a healthcare provider for evaluation of their symptoms and provide treatment options.

Today, COVID-19 remains the third leading cause of death in the U.S. There are also almost 200 million Americans who suffer from one or more of the underlying health conditions that put them at risk of getting the virus, according to Ada. Unfortunately, many of them aren't aware of their increased risk to COVID.

Daniel Nathrath, CEO and co-founder of Ada, said the COVID-19 Care Journey aims to "significantly reduce the time from testing to treatment for users, and (Ada) firmly believe(s) that it has the potential to improve health outcomes for millions."

The online platform hosts an independent telehealth and ePharmacy provider option. Users can learn whether they are at high risk of developing severe COVID-19 using the Ada Antiviral Treatment Eligibility Questionnaire, which is a personalized self-assessment tool based on CDC, FDA and NIH guidelines.

If a user is at high risk they can assess their options for consulting a healthcare provider and connect with them through telehealth to evaluate their symptoms and treatment eligibility within 2 hours, for a low out of pocket cost, according to Ada.

If prescribed, users can receive a prescription for an authorized oral treatment for COVID for same-day pick up at a local pharmacy. Ada shared future plans to expand the platform to offer the option of home medication delivery.

"Connected digital health initiatives are a key step in lower cost, faster, more equitable and more convenient access to healthcare," said JoyL Silva, global and U.S. Antiviral Franchise lead at Pfizer. "Our collaboration with Ada is designed to educate patients on high-risk factors for severe COVID-19 and introduce choices for people to access a provider and learn about treatment options."

Users can also receive an assessment by conducting a self-screening in the Ada app or following a symptom assessment in the Ada app which indicates COVID-19 as a possible condition.